 CTI BioPharma has reported a better-than-expected Q3 print of 18.5M, which is a 40 growth QoQ, and we expect this growth to continue reaching close to USD60M in FY2022. CTICs Vonjo Pacritinib is a differentiated late-stage JAK2IRAK4FLT3CSF1R inhibitor for the treatment of myelofibrosis in patients with severe thrombocytopenia platelets 